Clinical trials: Bladder Tumors
Bladder Cancer, Urothelial Carcinoma
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
This is a randomized, open-label Phase 2 clinical trial to evaluate whether suppression of Hsp27 (Heat shock protein 27) production using OGX-427, a second-generation antisense oligonucleotide (ASO), in combination with docetaxel…
- Trial name
- NCT01780545
- Testing
- OGX-427, Docetaxel
- Where
- 35 sites in United States
- Volunteers
- 200 people
- Sponsor
- Noah Hahn, M.D.
Bladder Cancer
Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
The purpose of this study is to perform a secondary analysis of SWOG 8710 to assess NLRs value as a biomarker. Specifically, the investigators test two hypotheses: 1) that baseline NLR is correlated with overall survival after…
- Trial name
- NCT02756637
- Where
- United States
- Volunteers
- 634 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Urinary Bladder Cancer, Urinary Bladder Neoplasm
Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
There is a relation between inflammatory cells and the prognosis of tumors (cancer colon, renal, liver, and urinary bladder). In this study, the investigators will link the Neutrophils to Lymphocytes ratio to the response to…
- Conditions
- Urinary Bladder Cancer, Urinary Bladder Neoplasm, BCG, Trans Urethral Resection of a Bladder Tumor
- Trial name
- NCT05946369
- Testing
- Neutrophil to lymphocyte ratio
- Where
- Egypt
- Volunteers
- 96 people
- Sponsor
- Ain Shams University
Urothelial Carcinoma, Bladder Cancer
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
This is a single-armed, multicenter, non-blinded phase 2 study to assess efficacy of induction ipilimumab + nivolumab followed by chemoradiation to spare the bladder in urothelial bladder cancer.
- Trial name
- Indi-Blade (NCT05200988)
- Testing
- Ipilimumab + nivolumab
- Where
- 3 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Non-muscle Invasive Bladder Cancer
A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer
Prior to performing any study specific procedure (including screening procedures to determine eligibility), a signed consent form will be obtained for each subject.
- Trial name
- Hydeal Cyst (NCT06245603)
- Testing
- Hydeal Cyst®
- Where
- 9 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Bladder Cancer, Cystectomy
A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients
The purpose of this study is to test a randomized, controlled diet and physical activity intervention designed to be simple and address barriers to participation in lifestyle intervention among 16 urinary bladder cancer patients.
- Conditions
- Bladder Cancer, Cystectomy, Chemotherapy
- Trial name
- BOOST (NCT06002269)
- Testing
- Dietary and Exercise Intervention
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Bladder Cancer
Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer
Radical cystectomy remains the gold standard treatment for invasive non metastatic transitional cell cancer (TCC) of the bladder.
- Trial name
- VESPER (NCT01812369)
- Testing
- GEMCITABINE CISPLATINE, METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Rouen
Uterine Cancer, Cervical Cancer
Intensity Modulated Radiotherapy (IMRT) for the Pelvis Post-Hysterectomy
The goal of this clinical research study is to use CT scans to find any changes in position of the vagina and pelvic lymph node areas during the course of IMRT radiation therapy.
- Conditions
- Uterine Cancer, Cervical Cancer, Endometrial Cancer
- Trial name
- NCT00508703
- Testing
- Intensity Modulated Radiotherapy (IMRT), CT Scan
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Measuring Surgical Recovery After Radical Cystectomy
The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions.
- Trial name
- NCT03193970
- Testing
- Post-Operative Recovery Registry
- Where
- 10 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.
- Trial name
- COXEN (NCT02177695)
- Testing
- Gemcitabine, Cisplatin, Methotrexate
- Where
- 566 sites in United States
- Volunteers
- 237 people
- Sponsor
- SWOG Cancer Research Network
Urothelial Cancer
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel…
- Trial name
- NCT02256436
- Testing
- pembrolizumab, paclitaxel, vinflunine
- Volunteers
- 542 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer, Renal Cancer
Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells
Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells
- Trial name
- NCT05108077
- Testing
- cytokine-induced killer cells, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 20 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Urinary Bladder Neoplasms
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor…
- Trial name
- NCT04172675
- Testing
- Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C)
- Where
- 150 sites in United States, Argentina and 15 more
- Volunteers
- 107 people
- Sponsor
- Janssen Research & Development, LLC
Carcinoma of Urinary Bladder, Superficial
Combined Use of BCG and Interferon Alpha in Bladder Cancer
To compare the toxicity and efficacy of the combination of BCG and interferon alpha to standard dose and low dose BCG alone in high risk superficial bladder cancer
- Trial name
- NCT00330707
- Testing
- Bacillus Calmette Guerin and interferon alpha
- Where
- Singapore
- Volunteers
- 140 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer, Prostate Cancer
Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography
The primary objective of the study is to test a new radiotracer called 68Ga-NOTA-AE105 for PET imaging of uPAR (urokinase plasminogen activator receptor).
- Conditions
- Breast Cancer, Prostate Cancer, Urinary Bladder Cancer
- Trial name
- uPAR-PET (NCT02437539)
- Testing
- Injection of 68Ga-NOTA-AE105, Positron Emission Tomography scans
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Bladder Cancer, Non-Muscle-Invasive Urothelial Carcinoma
BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
The purpose of this study is to study the activity and effects of BGJ398 on bladder cancer tumors that are confined to the lining of the bladder.
- Trial name
- NCT02657486
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urethral Stricture, Bladder (Urothelial, Transitional Cell) Cancer
The Impact of Age and Sex on Anticipated and Experienced Pain in First-Time Outpatient Flexible Cystoscopy
Cystoscopy is a procedure frequently performed in daily urological practice for the diagnosis of various urological conditions, including bladder tumors, benign prostatic hyperplasia, recurrent cystitis, and urethral strictures.
- Conditions
- Urethral Stricture, Bladder (Urothelial, Transitional Cell) Cancer, Benign Prostate Obstruction (BPO)
- Trial name
- PAINCYST (NCT07375641)
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Kayseri Education and Research Hospital
NMIBC
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
This expanded access protocol is designed to provide Recombinant Mycobacterium BCG (rMBCG) to patients with Non-muscle invasive bladder cancer (NMIBC) who are eligible to receive TICE® BCG, may benefit from its use, and who are…
- Trial name
- NCT06810141
- Testing
- rMBCG
- Where
- 66 sites in United States
- Sponsor
- ImmunityBio, Inc.
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease.
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Trial name
- NCT06529822
- Testing
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.